Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of oral TAC-101 as second-line treatment in advanced hepatocellular carcinoma after sorafenib
2007-007629-32Phase 2Terminated
- Sponsor
- Taiho Oncology
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing TAC-101 arm with Placebo arm (2 arms). Primary endpoint: Overall Survival. Started Mar 2008; status: terminated.
02
Drugs
TAC-101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2007-007629-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007629-32.